Biomedical Bonding AB’s novel primer formulation has been granted a patent in China.
The primer is an enabling technology and part of the Bonevolent™ platform towards strong adhesion to metal implants, for use in resin-based fixation of bone fractures and dental restoration treatments.
Biomedical Bonding AB has secured a unique primer formulation patent for use together with its resin-based composite technology, a first of a kind universal fracture fixation solution that is going to be revolutionary in the world of surgery and treatments for fractures. The recently granted patent is now valid in both Europe and China. It would serve essential in BMB’s path towards commercialisation.
“We are happy to obtain one additional patent to further strengthen our Bonevolent™ IPR portfolio in key geographical regions. The primer patent family is unique and it protects all key components that collectively enable superior resins-based fixation of bones, metal or teeth. It is a critical component that will allow BMB to pursue its vision towards personalized treatment of both bone fractures fixation as well dental restorations”, says Founder and CEO, Prof. Michael Malkoch.